Logo image
Back
Adverse drug reactions and drug interactions in the treatment of hospitalized patients with coronavirus disease 2019 (COVID-19)
Journal article   Open access   Peer reviewed

Adverse drug reactions and drug interactions in the treatment of hospitalized patients with coronavirus disease 2019 (COVID-19)

Tatiana A. Marins, Alexandre R. Marra, Michael B. Edmond, Ligia Regina Prystaj Colombo, Sthephanie Favalli Vieira, Fernanda de Oliveira Xavier, Alessandra Gomes Chauvin, João Renato Rebello Pinho, Silvana M. de Almeida and Marcelino Souza Durão Junior
Antimicrobial Stewardship & Healthcare Epidemiology, Vol.1(1), e38
2021
DOI: 10.1017/ash.2021.196
PMCID: PMC9495530
PMID: 36168493
Appears in  UI Libraries Support Open Access
url
https://doi.org/10.1017/ash.2021.196View
Published (Version of record) Open Access

Abstract

Abstract Objectives: To identify drugs that were administered off label to hospitalized patients with suspected coronavirus disease 2019 (COVID-19) and to identify adverse drug reactions (ADRs) and drug–drug interactions associated with these therapies. Methods: This case–control study was conducted in a Brazilian hospital from March to April 2020 among patients with suspected COVID-19, comparing those with positive severe acute respiratory coronavirus virus 2 (SARS-CoV-2) reverse-transcriptase polymerase chain reaction (RT-PCR) results and those with negative results. Results: The most commonly used medications in both groups were azithromycin and hydroxychloroquine. There was a significantly higher prevalence of reactions among patients with positive RT-PCR for SARS-CoV-2 (48.5% vs 28.8%; P = .008) in the propensity score–matched cohort, and the most commonly reported ADRs among these patients were diarrhea (43.8%), elevated liver enzymes (31.3%), and nausea and vomiting (29.7%). Conclusions: Our data demonstrate that ADRs and drug–drug interactions are common with off-label treatments for COVID-19.
 UIOWA OA Agreement

Details

Metrics

18 Record Views
Logo image